Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
FCRL2 - Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy effect on chronic lymphocytic leukemia
GEO DataSets Gene Profile neighbors Chromosome neighbors Homologene neighbors
FCRL2 - NOTCH antagonist SAHM1 effect on T-ALL cell lines
FCRL2 - Histone deacetylase inhibitor and hypomethylating agent effect on diffuse large B-cell lymphoma cell lines
FCRL2 - Nodular lymphocyte-predominant Hodgkin lymphoma: lymphocytic and histiocytic cells
FCRL2 - Chronic lymphocytic leukemia response to antisense Bcl-2 inhibitor SPC2996: peripheral blood
FCRL2 - Coronary artery atherosclerosis
FCRL2 - Follicular lymphoma and higher grade diffuse large B-cell lymphoma patients: lymph node tumor biopsies
FCRL2 - Chronic lymphocytic leukemia: peripheral blood, bone marrow and lymph node matched samples
FCRL2 - Chronic lymphocytic leukemia: peripheral blood B cells (HG-U133B)
FCRL2 - Chronic B-lymphocytic leukemia: peripheral blood
FCRL2 - B-cell chronic lymphocytic leukemia cell type and prognosis
FCRL2 - Follicular lymphomas and response to rituximab
FCRL2 - Systemic juvenile idiopathic arthritis and non-systemic JIA subtypes: peripheral blood mononuclear cells
FCRL2 - Chronic lymphocytic leukemia with chromosomal deletion 11q: peripheral blood CD19+ cells
FCRL2 - N-terminal truncated GATA1-mutant effect on fetal CD34+ hematopoietic stem and progenitor cells: time course
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on